• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Role of Toll-like receptors in the pathogenesis of COVID-19.Toll 样受体在 COVID-19 发病机制中的作用。
J Med Virol. 2021 May;93(5):2735-2739. doi: 10.1002/jmv.26826. Epub 2021 Feb 9.
2
TLRs: Innate Immune Sentries against SARS-CoV-2 Infection.TLRs:对抗 SARS-CoV-2 感染的先天免疫哨兵。
Int J Mol Sci. 2023 Apr 29;24(9):8065. doi: 10.3390/ijms24098065.
3
Differential Expression Patterns of Toll-like Receptors in COVID-19 Patients.COVID-19患者中Toll样受体的差异表达模式
Front Biosci (Landmark Ed). 2023 Nov 28;28(11):307. doi: 10.31083/j.fbl2811307.
4
Innate Receptor Activation Patterns Involving TLR and NLR Synergisms in COVID-19, ALI/ARDS and Sepsis Cytokine Storms: A Review and Model Making Novel Predictions and Therapeutic Suggestions.固有受体激活模式涉及 COVID-19、ALI/ARDS 和脓毒症细胞因子风暴中的 TLR 和 NLR 协同作用:综述和模型制作新的预测和治疗建议。
Int J Mol Sci. 2021 Feb 20;22(4):2108. doi: 10.3390/ijms22042108.
5
Toll-like receptor (TLRs) agonists and antagonists for COVID-19 treatments.用于治疗新型冠状病毒肺炎的Toll样受体(TLRs)激动剂和拮抗剂
Front Pharmacol. 2022 Sep 7;13:989664. doi: 10.3389/fphar.2022.989664. eCollection 2022.
6
Innate immunity: the first line of defense against SARS-CoV-2.先天免疫:抵御 SARS-CoV-2 的第一道防线。
Nat Immunol. 2022 Feb;23(2):165-176. doi: 10.1038/s41590-021-01091-0. Epub 2022 Feb 1.
7
In silico analyses on the comparative sensing of SARS-CoV-2 mRNA by the intracellular TLRs of humans.关于 SARS-CoV-2 mRNA 在人类细胞内 TLR 上的比较感应的计算机分析。
J Med Virol. 2021 Apr;93(4):2476-2486. doi: 10.1002/jmv.26776. Epub 2021 Jan 12.
8
Current Understanding of the Innate Control of Toll-like Receptors in Response to SARS-CoV-2 Infection.目前对 SARS-CoV-2 感染中 Toll 样受体先天控制的理解。
Viruses. 2021 Oct 22;13(11):2132. doi: 10.3390/v13112132.
9
An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants.TLR 对 SARS-CoV-2 感染反应的最新研究进展概述及 TLR 激动剂作为 SARS-CoV-2 疫苗佐剂的潜力。
Viruses. 2021 Nov 18;13(11):2302. doi: 10.3390/v13112302.
10
The dysfunctional innate immune response triggered by Toll-like receptor activation is restored by TLR7/TLR8 and TLR9 ligands in cutaneous lichen planus.TLR7/TLR8 和 TLR9 配体可恢复皮肤扁平苔藓中由 Toll 样受体激活引发的功能失调的固有免疫反应。
Br J Dermatol. 2015 Jan;172(1):48-55. doi: 10.1111/bjd.13214. Epub 2014 Nov 20.

引用本文的文献

1
A mini-review of the relationship between intestinal microecology and acute respiratory distress syndrome.肠道微生态与急性呼吸窘迫综合征关系的综述
PeerJ. 2025 Aug 29;13:e19995. doi: 10.7717/peerj.19995. eCollection 2025.
2
Altered Gut Microbiota and Predicted Immune Dysregulation in Early Childhood SARS-CoV-2 Infection.幼儿感染新冠病毒后肠道微生物群的改变及预测的免疫失调
Microorganisms. 2025 Aug 12;13(8):1879. doi: 10.3390/microorganisms13081879.
3
SARS-CoV-2 Pneumonia: Advances in Diagnosis and Treatment.严重急性呼吸综合征冠状病毒2型肺炎:诊断与治疗进展
Microorganisms. 2025 Jul 31;13(8):1791. doi: 10.3390/microorganisms13081791.
4
Effect of Pituitary-Target Gland Axis on RAAS in the Context of COVID-19.在2019冠状病毒病背景下垂体-靶腺轴对肾素-血管紧张素-醛固酮系统的影响
Int J Med Sci. 2025 Jul 25;22(13):3439-3453. doi: 10.7150/ijms.114924. eCollection 2025.
5
Design of a Multi-Epitope Vaccine Based on Cathepsin B and Evaluation of Immunological Responses in Mice.基于组织蛋白酶B的多表位疫苗设计及小鼠免疫反应评估
Int J Mol Sci. 2025 Jul 20;26(14):6971. doi: 10.3390/ijms26146971.
6
Luteolin-Rich Extract from (Blanco) Merr. Root Alleviates SARS-CoV-2 Spike Protein-Stimulated Lung Inflammation via Inhibition of MAPK/NLRP3 Inflammasome Signaling Pathways.来自(布兰科)梅尔根特海姆氏根的富含木犀草素的提取物通过抑制丝裂原活化蛋白激酶/核苷酸结合寡聚化结构域样受体蛋白3炎性小体信号通路减轻严重急性呼吸综合征冠状病毒2刺突蛋白刺激的肺部炎症。
Life (Basel). 2025 Jul 5;15(7):1077. doi: 10.3390/life15071077.
7
Immuno-informatics analyses of important esophageal cancer associated viruses for multi-epitope vaccine design.用于多表位疫苗设计的重要食管癌相关病毒的免疫信息学分析
Front Immunol. 2025 Jul 8;16:1587224. doi: 10.3389/fimmu.2025.1587224. eCollection 2025.
8
Deciphering TLR and JAK/STAT pathways: genetic variants and targeted therapies in COVID-19.解析Toll样受体(TLR)和JAK/STAT信号通路:新型冠状病毒肺炎中的基因变异与靶向治疗
Mol Biol Rep. 2025 Jul 18;52(1):733. doi: 10.1007/s11033-025-10843-2.
9
Serum syndecan-1 is related to severity and prognosis of COVID-19 patients: a perspective cohort study.血清syndecan-1与COVID-19患者的严重程度和预后相关:一项前瞻性队列研究。
BMC Pulm Med. 2025 Jul 2;25(1):296. doi: 10.1186/s12890-025-03768-w.
10
Emerging trends and focus of Toll-like receptors in kidney diseases: a 20-year bibliometric analysis.肾脏疾病中Toll样受体的新趋势与研究重点:一项20年的文献计量分析
Front Med (Lausanne). 2025 Jun 13;12:1599196. doi: 10.3389/fmed.2025.1599196. eCollection 2025.

本文引用的文献

1
Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.预防性鼻腔内给予 TLR2/6 激动剂可减少 SARS-CoV-2 挑战雪貂模型的上呼吸道病毒脱落。
EBioMedicine. 2021 Jan;63:103153. doi: 10.1016/j.ebiom.2020.103153. Epub 2020 Dec 3.
2
The Inflammasome in Times of COVID-19.COVID-19 时期的炎症小体
Front Immunol. 2020 Oct 8;11:583373. doi: 10.3389/fimmu.2020.583373. eCollection 2020.
3
Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.利用免疫系统克服 COVID-19 中的细胞因子风暴并降低病毒载量:疾病各阶段和治疗药物综述。
Virol J. 2020 Oct 15;17(1):154. doi: 10.1186/s12985-020-01415-w.
4
COVID-19 Patients Upregulate Toll-like Receptor 4-mediated Inflammatory Signaling That Mimics Bacterial Sepsis.COVID-19 患者上调 Toll 样受体 4 介导的炎症信号,模拟细菌性败血症。
J Korean Med Sci. 2020 Sep 28;35(38):e343. doi: 10.3346/jkms.2020.35.e343.
5
Toll-like receptors and COVID-19: a two-faced story with an exciting ending.Toll样受体与新型冠状病毒肺炎:一个有着激动人心结局的双面故事。
Future Sci OA. 2020 Jul 30;6(8):FSO605. doi: 10.2144/fsoa-2020-0091.
6
Interleukin-6 and severe COVID-19: a systematic review and meta-analysis.白细胞介素-6 与重症 COVID-19:系统评价和荟萃分析。
Eur Cytokine Netw. 2020 Jun 1;31(2):44-49. doi: 10.1684/ecn.2020.0448.
7
SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology.新冠病毒引发的中性粒细胞胞外诱捕网介导 COVID-19 病理学。
J Exp Med. 2020 Dec 7;217(12). doi: 10.1084/jem.20201129.
8
Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective.从分子机制和免疫反应角度治疗新冠肺炎的当前方法。
Saudi Pharm J. 2020 Nov;28(11):1333-1352. doi: 10.1016/j.jsps.2020.08.024. Epub 2020 Sep 1.
9
Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19.咪喹莫特 - 一种 Toll 样受体 7 激动剂 - 是治疗 COVID-19 的理想选择。
Environ Res. 2020 Sep;188:109858. doi: 10.1016/j.envres.2020.109858. Epub 2020 Jun 23.
10
mTOR inhibition and p53 activation, microRNAs: The possible therapy against pandemic COVID-19.mTOR抑制与p53激活、微小RNA:对抗大流行新冠病毒病的可能疗法
Gene Rep. 2020 Sep;20:100765. doi: 10.1016/j.genrep.2020.100765. Epub 2020 Jun 30.

Toll 样受体在 COVID-19 发病机制中的作用。

Role of Toll-like receptors in the pathogenesis of COVID-19.

机构信息

Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.

Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.

出版信息

J Med Virol. 2021 May;93(5):2735-2739. doi: 10.1002/jmv.26826. Epub 2021 Feb 9.

DOI:10.1002/jmv.26826
PMID:33506952
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8014260/
Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a pandemic since March 2020. The exact pathogenesis of SARS-CoV-2 and the role of each component of the innate and adaptive immune system is still unknown. However, available data from other coronavirus families, such as SARS-CoV and the Middle East respiratory syndrome and also new findings could be useful for a better understanding of SARS-CoV-2. Toll-like receptors (TLR) play an important role in recognition of viral particles and activation of the innate immune system. Activation of TLR pathways leads to secretion of pro-inflammatory cytokines, such as interleukin-1 (IL-1), IL-6, and tumor necrosis factor-α, as well as type 1 interferon. Different TLRs, like TLR2, TLR3, TLR4, TLR6, TLR7, TLR8, and TLR9 are potentially important in COVID-19 infection. It is also worth mentioning that we should bear in mind both the beneficial and harmful effects of TLR in confronting COVID-19 infection. TLRs could be a potential target in controlling the infection in the early stages of disease and production of vaccine against SARS-CoV-2.

摘要

新型冠状病毒病(COVID-19)由严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)引起,自 2020 年 3 月以来已导致大流行。SARS-CoV-2 的确切发病机制以及先天和适应性免疫系统的各个成分的作用仍不清楚。然而,来自其他冠状病毒家族(例如 SARS-CoV 和中东呼吸综合征)的现有数据以及新发现可能有助于更好地了解 SARS-CoV-2。Toll 样受体(TLR)在识别病毒颗粒和激活先天免疫系统方面起着重要作用。TLR 途径的激活导致促炎细胞因子(如白细胞介素-1(IL-1)、IL-6 和肿瘤坏死因子-α)以及 I 型干扰素的分泌。不同的 TLR,如 TLR2、TLR3、TLR4、TLR6、TLR7、TLR8 和 TLR9,在 COVID-19 感染中可能具有重要意义。值得一提的是,我们应该记住 TLR 在对抗 COVID-19 感染时既有有益的影响也有有害的影响。TLR 可能是在疾病早期控制感染和生产针对 SARS-CoV-2 的疫苗的潜在目标。